INFINITY PHARMA
InactiveOverview
Overview
Official details
Source: KBO- Status
- Absorbed by ACA PHARMA merger by absorption, July 2021
- Activity
- No activity registered in the KBO
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Financial position
No score
Annual accounts 2020
- Turnover
- €5.8m
- ▲ 11.3%
- Profit
- €177,320
- ▼ 38.9%
- Equity
- €1.5m
- ▲ 13.6%
- Total assets
- €3.2m
- ▲ 14.9%
- Staff
- 9 FTE
- ▲ 7.1%
Financials
Financials · financial year 2020, full format
Annual accounts 2020 filed on 25-05-2021 PDF all 14 filings
Turnover
€5.8m▲ 11.3%
2019 · €5.2m
EBIT margin
6.9%▼ 4.0pp
2019 · 10.9%
Net result
€177,320▼ 38.9%
2019 · €290,417
Working capital
€1.5m▲ 15.0%
2019 · €1.3m
Multi-year overview
2018 to 2020, 3 financial yearsTurnover
€5.8m
▲ 11.3%
2020
20182020
Operating result
€404,614
▼ 29.1%
2020
20182020
Net result
€177,320
▼ 38.9%
2020
20182020
EBIT margin
6.9%
▼ 4.0pp
2020
20182020
Equity
€1.5m
▲ 13.6%
2020
20182020
Total assets
€3.2m
▲ 14.9%
2020
20182020
Debt
€1.7m
▲ 16.4%
2020
20182020
Working capital
€1.5m
▲ 15.0%
2020
20182020
Staff (FTE)
9
▲ 7.1%
2020
20182020
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line201820192020
Turnover€5.1m-€5.2m▲ 2.6%€5.8m▲ 11.3%
Operating result€0.7m-€0.6m▼ 17.3%€0.4m▼ 29.1%
Net result€0.4m-€0.3m▼ 26.4%€0.2m▼ 38.9%
EBIT margin13.5%-10.9%▼ 2.6pp6.9%▼ 4.0pp
Equity€1.0m-€1.3m▲ 28.5%€1.5m▲ 13.6%
Total assets€5.0m-€2.8m▼ 44.2%€3.2m▲ 14.9%
Debt€4.0m-€1.5m▼ 62.8%€1.7m▲ 16.4%
Working capital€1.0m-€1.3m▲ 31.7%€1.5m▲ 15.0%
Staff (FTE)7.6-8.4▲ 10.5%9▲ 7.1%
The operating result for 2020 is 29% lower than in 2019 and the lowest since 2018. It is the second fall in a row.
Balance-sheet composition
2020 in colour, 2019 as the grey bar beneath
Assets €3.2m
Fixed assets
€16,852 ▼ 43.7%
Current assets
€3.2m ▲ 15.5%
Equity and liabilities €3.2m
Equity
€1.5m ▲ 13.6%
Provisions
€3,603 ▼ 54.5%
Debt
€1.7m ▲ 16.4%
Debt's share of the balance-sheet total rises from 53.0% to 53.7%. Equity and debt are higher.
Key figures and ratios
EBITDA
€417,687▼
2019 · €603,989
Cash flow
€190,394▼
2019 · €323,547
Current ratio
1.86▼
2019 · 1.87
Quick ratio
1.47▲
2019 · 1.27
ROE
11.9%▼
2019 · 22.2%
ROA
5.5%▼
2019 · 10.4%
Interest coverage
27.21▼
2019 · 29.70
Debt ≤ 1 year
€1.7m▲
2019 · €1.5m
Income taxes
€85,584▼
2019 · €153,292
Customer credit
1 day▼
2019 · 7 days
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Annual accounts
| Line | 2018 | 2019 | 2020 | Change |
|---|---|---|---|---|
| Turnover70 | €5.1m | €5.2m | €5.8m | ▲ 11.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.04m | €0.03m | €0.01m | ▼ 60.5% |
| Operating profit (loss)9901 | €0.7m | €0.6m | €0.4m | ▼ 29.1% |
| Recurring financial income75 | €0.02m | €309 | €80 | ▼ 74.2% |
| Recurring financial charges65 | €0.1m | €0.1m | €0.1m | ▲ 11.2% |
| Debt charges650 | €0.05m | €0.02m | €0.02m | ▼ 24.5% |
| Profit (loss) for the period before taxes9903 | €0.6m | €0.4m | €0.3m | ▼ 40.7% |
| Income taxes67/77 | €0.2m | €0.2m | €0.09m | ▼ 44.2% |
| Profit (loss) for the period9904 | €0.4m | €0.3m | €0.2m | ▼ 38.9% |
| Profit (loss) for the period to be appropriated9905 | €0.4m | €0.3m | €0.2m | ▼ 38.9% |
| Line | 2018 | 2019 | 2020 | Change |
|---|---|---|---|---|
| Assets | ||||
| Total assets20/58 | €5.0m | €2.8m | €3.2m | ▲ 14.9% |
| Fixed assets21/28 | €0.06m | €0.03m | €0.02m | ▼ 43.7% |
| Intangible fixed assets21 | €0.02m | €0.008m | €0.003m | ▼ 64.0% |
| Tangible fixed assets22/27 | €0.03m | €0.02m | €0.01m | ▼ 37.3% |
| Financial fixed assets28 | €364 | €364 | €364 | = |
| Current assets29/58 | €5.0m | €2.8m | €3.2m | ▲ 15.5% |
| Stocks and contracts in progress3 | €0.7m | €0.9m | €0.7m | ▼ 22.9% |
| Amounts receivable within one year40/41 | €0.07m | €0.09m | €0.02m | ▼ 76.7% |
| Cash at bank and in hand54/58 | €4.2m | €1.8m | €2.5m | ▲ 41.0% |
| Equity and liabilities | ||||
| Total equity and liabilities10/49 | €5.0m | €2.8m | €3.2m | ▲ 14.9% |
| Equity10/15 | €1.0m | €1.3m | €1.5m | ▲ 13.6% |
| Contributions10/11 | €0.1m | €0.1m | €0.1m | = |
| Reserves13 | €0.01m | €1.2m | €1.4m | ▲ 14.7% |
| Profit (loss) carried forward14 | €0.9m | - | - | - |
| Provisions and deferred taxes16 | €0.01m | €0.008m | €0.004m | ▼ 54.5% |
| Amounts payable17/49 | €4.0m | €1.5m | €1.7m | ▲ 16.4% |
| Amounts payable within one year42/48 | €4.0m | €1.5m | €1.7m | ▲ 15.9% |
| Trade debts44 | €0.8m | €0.9m | €1.2m | ▲ 43.0% |
| Line | 2018 | 2019 | 2020 | Change |
|---|---|---|---|---|
| Profit (loss) for the period9904 | €0.4m | €0.3m | €0.2m | ▼ 38.9% |
| + Depreciation and write-downs630 | €0.04m | €0.03m | €0.01m | ▼ 60.5% |
| Operating cash flow (approximation) | €0.4m | €0.3m | €0.2m | ▼ 41.2% |
| Investment in fixed assets (approximation) | - | -€0.006m | €0 | - |
| Change in cash | - | -€2.5m | €0.7m | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 14 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2020 | full format | 25-05-2021 | 2021-15200033 | |
| 31-12-2019 | full format | 31-05-2020 | 2020-13900407 | |
| 31-12-2018 | full format | 16-05-2019 | 2019-13300507 | |
| 31-12-2017 | full format | 23-05-2018 | 2018-13600433 | |
| 31-12-2016 | full format | 24-05-2017 | 2017-13300316 | |
| 31-12-2015 | full format | 10-06-2016 | 2016-16900566 | |
| 31-12-2014 | full format | 16-06-2015 | 2015-17600600 | |
| 31-12-2013 | full format | 04-07-2014 | 2014-27800085 | |
| 31-12-2012 | full format | 26-06-2013 | 2013-23600542 | |
| 31-12-2011 | full format | 31-05-2012 | 2012-14700482 |
Board & ownership
Directors
Directors
Owners and capital
Network & group
Acquisitions and mergers
1 transactionTaken over by:ACA PHARMA
Connections & network
The network starts from the shareholders of INFINITY PHARMA. Every company they also own or run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
2021
2020
31-12
Financial
Weakest financial yearnet €177,320 ▼38.9%
The net result drops to €177,320, the lowest from 2018 to 2020.
31-05
full format · 61 days before the deadline
2019
16-05
full format · 76 days before the deadline
2018
23-05
full format · 69 days before the deadline
2017
24-05
full format · 68 days before the deadline
2016
10-06
full format · 51 days before the deadline
2015
16-06
full format · 45 days before the deadline
2014
04-07
full format · 27 days before the deadline
2013
26-06
full format · 35 days before the deadline
2012
31-05
full format · 61 days before the deadline
2006
11-09
35 publications in the Belgian Official Gazette, the last on 26-07-2021
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Inactive
Absorbed by ACA PHARMA in July 2021
INFINITY PHARMA is no longer in the KBO register. ACA PHARMA took it over in a merger by absorption, published in the Belgian Official Gazette on 26 July 2021.
- Status
- Inactive
- Reason
- Merger by absorption"operation treated as a merger by absorption", Belgian Official Gazette, 26 July 2021 · act
- Absorbed by
- ACA PHARMA · 0416.616.681
- Last annual accounts
- financial year to 31 December 2020
- Last registered office
- Venecoweg 20A, 9810 Nazarethas published on 26 July 2021
- Legal form
- Public limited company
- First annual accounts
- financial year 2007